Atheon Bio
- Biotech or pharma, therapeutic R&D
Atheon Bio is a biotechnology startup pioneering the development of next-generation antibody therapeutics designed to overcome resistance in refractory solid tumors. Our first pipeline, ATN001, is a first-in-class monoclonal antibody that has demonstrated potent dual functionality: it inhibits abnormal tumor angiogenesis and reprograms the immune microenvironment to promote T cell infiltration and activation. Building on the differentiated biology and safety profile of ATN001,
Atheon Bio has expanded its pipeline to include two proprietary bispecific antibody programs that harness the immune-modulating properties of ATN001 in combination with clinically validated immuno-oncology and vascular targets, (1) ATN001/PD1 Bispecific Antibody and (2) ATN001/VEGF Bispecific Antibody for AMD. These bispecific programs demonstrate Atheon Bio’s broader vision of leveraging TME reprogramming across multiple therapeutic areas where angiogenesis and immune suppression are key pathological drivers.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}